MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahj.2023.06.012

Медицинская библиотека · American heart journal · 2023

Efficacy and safety of a bolus of half-dose r-SAK prior to primary PCI in ST-elevation myocardial infarction: Rationale and design of the OPTIMA-6 trial.

Li Chen, Eikelboom John W, Zhong Zihang, Zhang Xiwen, Liu Kun, Zhu Li, Yang Naiquan, Chen Xin, Wang Xiaoyan, Zhao Xin, Jiang Jun, Pu Jun, Zhao Bo, Zhang Fumin, Zhu Jun, Huang Jun, Kong Xiangqing, Yu Hao, Tan Chunyue, Zhang Wenhao, Wang Qin, Gong Xiaoxuan, Bai Jianling, Li Chunjian, Nanjing, China

СтатьяПротокол клинического исследованияПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Time to reperfusion is the key to the treatment of patients with ST-elevation myocardial infarction (STEMI). It is uncertain whether adjunctive thrombolytic therapy combined with contemporary antiplatelet agent ticagrelor improves outcomes as administered prior to primary percutaneous coronary intervention (PCI) expected to be performed within 120 minutes.

METHODS

OPTIMA-6 is a multicenter, randomized, double-blind, placebo-controlled, and superiority trial to evaluate the efficacy of a bolus of half-dose recombinant staphylokinase (r-SAK) vs placebo prior to timely primary PCI in patients with STEMI. Enrollment began in April 2023 and is expected to enroll 2,260 patients at approximately 50 centers. Patients with acute STEMI presenting ≤12 hours of symptom onset and expected to undergo primary PCI within 120 minutes but more than 30 minutes are to be randomized to a bolus of half-dose r-SAK or placebo. All recruited patients will be mandatory to take aspirin and ticagrelor and receive a bolus of loading dose heparin before the thrombolytic therapy. The primary efficacy endpoint is major adverse cardiovascular events (MACE) within 90 days, and the MACE is defined as a composite of all-cause death, reinfarction, unplanned target vessel revascularization, heart failure or cardiogenic shock, and major ventricular arrhythmia. The primary safety endpoints are major bleeding events (BARC 3, 5) within 90 days.

CONCLUSIONS

OPTIMA-6 will reveal the efficacy and safety of a contemporary facilitated PCI with a bolus of half-dose r-SAK in combination with ticagrelor in patients with STEMI.

Для цитирования: Li Chen, Eikelboom John W, Zhong Zihang, Zhang Xiwen, Liu Kun, Zhu Li, Yang Naiquan, Chen Xin, Wang Xiaoyan, Zhao Xin, Jiang Jun, Pu Jun, Zhao Bo, Zhang Fumin, Zhu Jun, Huang Jun, Kong Xiangqing, Yu Hao, Tan Chunyue, Zhang Wenhao, Wang Qin, Gong Xiaoxuan, Bai Jianling, Li Chunjian, Nanjing, China. Efficacy and safety of a bolus of half-dose r-SAK prior to primary PCI in ST-elevation myocardial infarction: Rationale and design of the OPTIMA-6 trial.. American heart journal. 2023. DOI: 10.1016/j.ahj.2023.06.012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.